The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis

NCT ID: NCT02211690

Last Updated: 2016-05-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-08-31
• Study Completion Date: 2016-02-29

Brief Summary

This study aims to describe the proportion of participants with non-occupational post-exposure prophylaxis (NPEP) failure, defined as NPEP non-completion (including loss to follow-up) at week 4 or primary HIV infection at week 4 or 12, excluding those participants who should and do cease study drug because:

1. The participant is found to be HIV-infected (study drugs will be ceased until the genotype of the infecting strain is determined)

2. The source is found to be HIV-uninfected

The primary study objectives are:

1. To describe on-drug adherence and regimen completion rates of 28 days of NPEP using dolutegravir (DTG) with co-formulated emtricitabine-tenofovir (FTC-TDF)

2. To describe the safety of 28 days of non-occupational post-exposure prophylaxis (NPEP) using dolutegravir with co-formulated emtricitabine-tenofovir

The study is a multi-site, prospective, open-label, non-randomized trial. One-hundred (100) eligible participants will receive dolutegravir (one tablet) with co-formulated emtricitabine-tenofovir, two tablets, once daily for 28 days based on one of the following exposures:

1. receptive anal intercourse with a source known to be HIV-infected; or

2. receptive anal intercourse with a source of unknown HIV status; or

3. insertive anal intercourse with a source known to be HIV-infected

There will be 7 study visits over a 12-week period. Follow-up post NPEP is for 8 weeks i.e. to week-12 post-exposure. Any participant who is intolerant of dolutegravir will be managed at the investigator's discretion.

Conditions

Human Immunodeficiency Virus

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

dolutegravir 50mg with co-formulated emtricitabine-tenofovir

One-hundred eligible participants will receive dolutegravir (1 x 50mg tablet) with co-formulated emtricitabine-tenofovir (1 tablet) once daily for 28 days

Group Type: EXPERIMENTAL

dolutegravir 50 mg (one tablet daily)

Intervention Type: DRUG

emtricitabine-tenofovir 300/200 mg (one tablet daily)

Intervention Type: DRUG

Interventions

dolutegravir 50 mg (one tablet daily)

Intervention Type: DRUG

emtricitabine-tenofovir 300/200 mg (one tablet daily)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Man who has sex with men

2. Age at least 18 years

3. Potential HIV exposure following:

• receptive anal intercourse with a source known to be HIV-infected; or
• receptive anal intercourse with a source of unknown HIV status; or
• insertive anal intercourse with a source known to be HIV-infected

4. Able to provide written, informed consent

5. Able to commit to the study visits

Exclusion Criteria

1. Non-sexual exposure

2. Exposure occurring during sex between a man and a woman

3. HIV infection diagnosed on baseline testing (antibody, Western blot, proviral DNA) including indeterminate serology consistent with possible primary HIV infection

4. Use of any medication contra-indicated with DTG, FTC or TDF

5. Use of any medication that effects the concentration of dolutegravir and / or concomitant drug including: oxcarbazepine, phenytoin, phenobarbital, carbamazepine, rifampicin, metformin or St. John's wort (St John's wort can be stopped for the 28-day period of NPEP).

6. History or presence of allergy to DTG, FTC, TDF or their components

7. Alanine aminotransferase (ALT) ≥5 times the upper limit of the reference range or ALT ≥3 times and bilirubin ≥1.5 times the upper limit of the reference range

8. Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice) or known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)

9. Severe hepatic impairment (Class C) as determined by Child-Pugh classification

10. Serum estimated Glomerular Filtration Rate (eGFR) <60 mL/min/BSAc

11. Current therapy for hepatitis B infection

12. Serological evidence of chronic/active hepatitis B

13. Previous OPEP/NPEP containing DTG

14. A participant with a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study, or interfere with the participant's participation for the full duration of the study

15. Unable to complete study procedures

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

ViiV Healthcare Australia Pty. Ltd

UNKNOWN

Sponsor Role: collaborator

Andrew Carr

OTHER

Sponsor Role: lead

Responsible Party

Andrew Carr

Head Clinical research Program

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

St Vincent's Hospital Centre for Applied Medical Research

Darlinghurst, New South Wales, Australia

Sydney Sexual Health Centre

Sydney, New South Wales, Australia

Clinic 16, Royal North Shore Hospital

Sydney, New South Wales, Australia

Melbourne Sexual Health Centre

Carlton, Victoria, Australia

Alfred Hospital

Melbourne, Victoria, Australia

Countries

Australia

Other Identifiers

201047

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

2.0 dated 23 June 2014

Identifier Type: -

Identifier Source: org_study_id